

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(Use as many sheets as necessary)</i>			
Sheet	1	of	2
<i>Complete If Known</i>			
Application Number		10/576,733-Conf. #4494	
Filing Date		April 21, 2006	
First Named Inventor		Ian Taylor	
Art Unit		1643	
Examiner Name		K. A. Canella	
Attorney Docket Number 5181 [67859(303981)]			

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature /Karen A. Canella, Ph.D./ Date Considered 06/07/2009

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant." CITE NO.: Those applications which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.9(a)(2)(ii)(a)) because that application was filed after June 30, 2003 or is available in the IWF. "Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document by the two-letter code (WFO, USPTO, ST, etc.). For non-USPTO patent documents, the indication of the year of the reign of the Emperor must precede the name of the issuing country. "Year of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if applicable. "Applicant's name in a check mark box if English language transcription is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: May 7, 2009

Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	5181 [67859(303981)]
-------	---	----	---	------------------------	----------------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers., publisher, city and/or country where published.	T ^o
CA	S. S. W. Ng, et al.: "Effects of the Epidermal Growth Factor Receptor Inhibitor OSI-774, Tarceva, on Downstream Signaling Pathways and Apoptosis in Human Pancreatic Adenocarcinoma," Molecular Cancer Therapeutics, Vol. 1, No. 18, August 2002, pgs. 777-783.		
CB	M. R. Ricciardi et al.: "Flow Cytometric Monitoring of Constitutive MAPK Phosphorylation and Pharmacodynamic MEK/MAPK Inhibition in Primary AML Samples," The American Society of Hematology, Vol. 100, No. 11, Abstract No. 4610, December, 2002, pg. 270b		
CC	J. A. Aguirre-Ghiso, et al.: "ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK." Cancer Research, Vol. 63, No. 7, April, 2003, pgs. 1684-1695.		
CD	J-H Zhu, et al.: "Cytoplasmic Aggregates of Phosphorylated Extracellular Signal-Regulated Protein Kinases in Lewy Body Diseases," American Journal of Pathology, Vol. 161, No. 6, December, 2002, pgs. 2087-2098.		
CE	K. Jorgensen et al.: "Expression of Activated Extracellular Signal-Regulated Kinases 1/2 in Malignant Melanomas: Relationship with Clinical Outcome," Clinical Cancer Research, Vol. 9, November, 2003, pgs. 5325-5331.		
CF	S. Tanimura et al.: "Specific Blockade of the ERK Pathway Inhibits the Invasiveness of Tumor Cells: Down-Regulation of Matrix Metalloproteinase-3/-9/-14 and CD44," Biochemical and Biophysical Research Communications, Vol. 304, 2003, pgs. 801-806.		
CG	A. Adeyinka et al.: "Activated Mitogen-activated Protein Kinase Expression During Human Breast Tumorigenesis and Breast Cancer Progression," Clinical Cancer Research, Vol. 8, June, 2002, pgs. 1747-1753.		
CH	Z. Fu et al.: "Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis," Journal of the National Cancer Institute, Vol. 95, No. 12, June 18, 2003, pgs. 878-889.		

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	06/07/2009
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/